2023年欧洲肿瘤内科学会乳腺癌大会（ESMO BC）将于5月11日至13日（当地时间，北京时间-6小时）在德国柏林国际展览中心正式召开。日前，大会官网公布了本次会议的详细日程，【肿瘤资讯】将口头报告研究题目整理如下，与君共赏！
Proffered Paper session 1
时间：2023.05.11 14:00 - 15:28
摘要号：185O
在 HER2 低表达不可切除和/或转移性乳腺癌患者中比较德曲妥珠单抗(T-DXd) 与医生选择的治疗：随机、Ⅲ期 DESTINY-Breast04 试验的详细安全性分析结局
英文标题：Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): a detailed safety analysis of the randomized, phase 3 DESTINY-Breast04 trial
讲者：Hope S. Rugo (San Francisco, CA, United States of America)
摘要号：186O
在 HER2 阳性转移性乳腺癌患者中比较T-DXd与医生选择的治疗：随机Ⅲ期DESTINY-Breast02研究中患者报告的结局
英文标题：Patient-reported outcomes (PROs) from DESTINY-Breast02, a randomized phase 3 study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC)
讲者：Tanja N. Fehm (Düsseldorf, Germany)
摘要号：187O
Capivasertib联合氟维司群用于芳香化酶抑制剂耐药的HR+/HER2- 晚期乳腺癌：Ⅲ期 CAPItello-291 试验的亚组分析结果
英文标题：Capivasertib and fulvestrant for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2- advanced breast cancer (ABC): subgroup analyses from the Phase 3 CAPItello-291 trial
讲者：Nicholas Turner (London, United Kingdom)
摘要号：188O
EMERALD 试验：口服 elacestrant vs 标准内分泌治疗在ER+/HER2- 晚期或转移性乳腺癌中的患者报告结局
英文标题：EMERALD trial analysis of patient-reported outcomes (PROs) in patients with ER+/HER2_ advanced or metastatic breast cancer (mBC) comparing oral elacestrant vs standard of care (SoC) endocrine therapy
讲者：Javier Cortes (Barcelona, Spain)
Proffered Paper session 2：Best abstracts
时间：2023.05.12 16:45 - 18:13
摘要号：124O
Patritumab deruxtecan (HER3-DXd) 治疗HR+/HER2- 乳腺癌和三阴性乳腺癌：SOLTI TOT-HER3机会窗试验 B 部分的结果
英文标题：Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple negative breast cancer (TNBC): results of part B of SOLTI TOT-HER3 window of opportunity trial
讲者：Ana Mafalda Antunes De Melo e Oliveira (Barcelona, Spain)
摘要号：189O
Ⅱ期ICARUS-BREAST01研究：通过生物标志物分析表征Patritumab Deruxtecan(HER3-DXd)在晚期乳腺癌患者中的治疗反应
英文标题：A phase 2 Study of Patritumab Deruxtecan (HER3-DXd), in patients (pts) with advanced breast cancer (ABC), with biomarker analysis to characterize response to therapy (ICARUS-BREAST01)
讲者：Barbara Pistilli (Villejuif, Cedex, France)
摘要号：LBA1
评估新辅助阿替利珠单抗联合化疗序贯开放辅助阿替利珠单抗治疗早期TNBC患者的安慰剂对照随机3期临床研究-IMpassion031试验最终分析
英文标题：Final analysis of the placebo-controlled randomised phase 3 IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC)
讲者：Carlos H. Barrios (Porto Alegre, Brazil)
摘要号：123O
阿替利珠单抗+HER2双重阻滞剂+表柔比星新辅助治疗HER2阳性早期乳腺癌的随机Ⅱ期试验（ABCSG-52/ATHENE）
英文标题：Randomized phase II trial of neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in early HER2-positive breast cancer (ABCSG-52 / ATHENE)
讲者：Gabriel Rinnerthaler (Salzburg, Austria)
Mini Oral session 1
时间：2023.05.11 16:45 - 18:07
摘要号：93MO
monarchE研究患者报告的长期结局：阿贝西利联合内分泌治疗辅助治疗淋巴结阳性、高危、HR+/HER2- 早期乳腺癌
英文标题：Long-term patient-reported outcomes from monarchE: abemaciclib plus endocrine therapy for adjuvant HR+, HER2-, node-positive, high-risk, early breast cancer (EBC)
讲者：Nadia Harbeck (Munich, Germany)
摘要号：94MO
DATA试验分析：BMI对接受（延长）内分泌治疗的绝经后HR+ 乳腺癌患者的预后和预测作用
英文标题：The prognostic and predictive effect of BMI in postmenopausal HR+ breast cancer patients receiving (extended) endocrine therapy - DATA trial analysis
讲者：Senna W.M. Lammers (Maastricht, Netherlands)
摘要号：260MO
ABCSG 22 Registry：绝经前激素受体阳性乳腺癌女性患者的长期预后
英文标题：Long term patient reported outcomes in premenopausal women with the hormone receptor positive breast cancer from ABCSG 22 Registry
讲者：Vesna Bjelic-Radisic (Wuppertal, Germany)
摘要号：190MO
KEYNOTE-119研究：18基因表达谱（GEP）与接受帕博丽珠单抗或化疗的转移性TNBC患者临床结局的相关性
英文标题：Association of 18-Gene Expression Profile (GEP) With Clinical Outcomes in Patients With Metastatic Triple-Negative Breast Cancer (mTNBC) Treated With Pembrolizumab (Pembro) or Chemotherapy (Chemo) in KEYNOTE-119
讲者：Javier Cortes (Barcelona, Spain)
摘要号：191MO
KEYNOTE-355研究：停用帕博利珠单抗前停止化疗的患者和发生免疫介导不良事件患者的结局
英文标题：KEYNOTE-355: Outcomes in patients who discontinued chemotherapy before pembrolizumab and in patients with immune-mediated AEs
讲者：Hope S. Rugo (San Francisco, CA, United States of America)
摘要号：1MO
ER- vs ER-low/HER2- 乳腺癌中的肿瘤免疫微环境
英文标题：Tumor immune microenvironment in ER-negative vs. ER-low, HER2-neg breast cancer
讲者：Davide Massa (Padova, Italy)
摘要号：2MO
HR+/HER2-转移性乳腺癌中免疫检查点标志物（IC）的表达水平
英文标题：Expression levels of immune checkpoint markers (IC) in hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC)
讲者：Anirudh Pabba (Leuven, Belgium)
Mini Oral session 2
时间：2023.05.12 08:45 - 10:15
摘要号：193MO
使用大型现实世界数据库开发深度学习模型，以预测转移性乳腺癌患者的总生存期
英文标题：Development of a Deep Learning model using a large real-world database to predict overall survival in patients with metastatic breast cancer (MBC)
讲者：Laura Vuduc (Gif sur Yvette, France)
摘要号：3MO
早期HR+/HER2-乳腺癌中的HER2表达和patritumab deruxtecan(HER3-DXd) 的早期应答：SOLTI-TOT-HER 3试验的相关性分析
英文标题：HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): a correlative analysis from SOLTI-TOT-HER3 trial
讲者：Fara Brasó-Maristany (Barcelona, Spain)
摘要号：192MO
DESTINY-Breast 04亚组分析：在HER2低表达、雌激素受体表达免疫组织化学为0~10%的转移性乳腺癌患者中比较T-DXd与医生选择的治疗
英文标题：DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0-10% metastatic breast cancer (mBC)
讲者：David A. A. Cameron (Edinburgh, United Kingdom)
摘要号：125MO
恩美曲妥珠单抗+帕妥珠单抗 (T-DM1+P) 和多西他赛+卡铂+曲妥珠单抗+帕妥珠单抗 (TCbHP) 新辅助治疗 HER2 阳性乳腺癌的长期结果：JBCRG20 研究（Neo-peaks）
英文标题：Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1+P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: JBCRG20 study (Neo-peaks)
讲者：Kenichi Inoue (Ina, Japan)
摘要号：126MO
HER2+ 乳腺癌中的HER2DX和病理学完全缓解：4项新辅助治疗研究的合并分析
英文标题：HER2DX and pathological complete response in HER2-positive breast cancer: a combined analysis of 4 neoadjuvant studies
讲者：Adrienne G. Waks (Boston, United States of America)
摘要号：171MO
具有生殖系TP53突变者的炎症谱及其与后续癌症发展的关系
英文标题：Inflammatory profiling of individuals with germline TP53 mutations (gTP53m) and its relationship to subsequent cancer development
讲者： Tarek Ben Ahmed (Villejuif, France)
摘要号：95MO
接受卡培他滨新辅助治疗后未完全缓解的早期TNBC患者的循环肿瘤DNA动力学
英文标题：Circulating tumor DNA (ctDNA) dynamics in patients (pts) receiving capecitabine (CAPE) for early-stage triple-negative breast cancer (eTNBC) with an incomplete response to neoadjuvant therapy (NAT)
讲者：Tanya Gupta (Palo Alto, CA, United States of America)
摘要号：4MO
接受奥拉帕利维持治疗的铂敏感晚期TNBC的同源重组状态
英文标题：Homologous recombination (HR) status of platinum responsive advanced triple negative breast cancers (aTNBC) treated with olaparib as maintenance therapy
讲者：Tira J. Tan (Singapore, Singapore)
Special session
时间：2023.05.13 09:00 - 09:50
摘要号：96MO
省略蒽环类用于TNBC患者的辅助治疗：非劣效性荟萃分析
英文标题：Omitting anthracyclines for the adjuvant treatment of patients with triple-negative breast cancer (TNBC): a non-inferiority meta-analysis
讲者：Fabio Girardi (Padova, Italy)
详细日程请点击下方网址：
https://cslide.ctimeetingtech.com/breast23hybrid/attendee/confcal/session
【会议日历】
柏林时间5月11日11:30开启卫星会，北京时间则为5月11日17:30（时差6小时）
排版编辑：肿瘤资讯-Paine
苏公网安备 32059002004080号
